New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2014
18:44 EDTAGN, JNJJ&J halting development of Botox competitor, WSJ says
Johnson & Johnson (JNJ) is ending development of an anti-wrinkle treatment that was aimed at challenging Allergan's (AGN) Botox, reports The Wall Street Journal, citing a company spokesman. Reference Link
News For JNJ;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 21, 2014
06:33 EDTAGNValeant price target raised to $182 from $167 at Cantor
Subscribe for More Information
October 20, 2014
12:36 EDTJNJOptions with decreasing implied volatility
Subscribe for More Information
12:23 EDTAGNAllergan holder Paulson encourages deal with Shire, Reuters says
Subscribe for More Information
09:25 EDTAGNValeant says talks to Ackman 'frequently'
Subscribe for More Information
09:08 EDTAGNValeant says not planning to walk away from Allergan deal before Dec. 18
Subscribe for More Information
08:58 EDTAGNValeant says still willing to improve bid for Allergan
Valeant (VRX) said would raise Allergan (AGN) bid "when time is right." Says hopes Allergan shareholders see that Valeant's operating model does work and will continue to work. Says Valeant (VRX), Allergan have "unique" business overlap. Says company "should" own Allergan. Says interests with Pershing, Ackman "aligned" on Allergan.
08:37 EDTAGNValeant says 'completely focused' on Allergan acquisition
Subscribe for More Information
08:14 EDTJNJPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
07:34 EDTAGNValeant says remains focused on completing Allergan transaction
Subscribe for More Information
07:30 EDTAGNValeant CEO says 'can bid more than anyone' in financially sound Allergan deal
Pearson says "we cannot stop" another company from making a bid that does not make economic sense, but he believes Valeant (VRX) can "bid more than anyone" for Allergan (AGN) in a deal that makes financial sense. Pearson says he has met with doctor groups and that 95% of those he's spoken with support Valeant's bid for Allergan. Valeant CEO J. Michael Pearson spoke on CNBC.
07:16 EDTAGNAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
06:28 EDTAGNAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 17, 2014
16:55 EDTJNJStocks end volatile week lower amid oil price plunge
Subscribe for More Information
10:37 EDTJNJOptions with decreasing implied volatility: ATLS JNJ XLNX JNK HYG
Subscribe for More Information
09:47 EDTAGNValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:45 EDTAGNAllergan not in deal talks with Actavis, CNBC reports
09:43 EDTAGNValeant not going to raise Allergan bid ahead of meeting, CNBC reports
Subscribe for More Information
08:57 EDTJNJPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTJNJPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:02 EDTJNJCovidien granted preliminary injunction against Ethicon's Harmonic ACE+7
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use